• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Tom Martens, MD, Talks about the Vision for CGM as Part of Primary Care for Type 2 Diabetes


MOBILE study lead author Tom Martens, MD, talks about the inherent benefits of CGM for T2D patients on basal insulin treated in primary care and also the challenges to this vision of patient care.

"If you look at people with type 2 diabetes, unquestionably the group that struggles the most is the group on insulin - and it's a relatively big group," said Thomas Martens, MD, lead investigator for the MOBILE study. "Insulin is hard."

The recently published MOBILE study found that in adults with poorly controlled type 2 diabetes (T2D) treated with basal, but not prandial, insulin, use of real time continuous glucose monitoring (CGM) significantly improved glycemic control and time in target glucose range compared to standard blood glucose monitoring. All MOBILE participants were recruited from and cared for in primary care during the study.

In an interview with Patient Care® Online, Dr Martens discussed the challenges to wider adoption of CGM technology in primary care of T2D, including primary care time constraints and clinician training, professional society review and recommendation, and payer reluctance.

Thomas W. Martens, MD, is a director at the Park Nicollet International Diabetes Center, an affiliate of Health Partners Institute in Minneapolis, Minnesota.

For additional interviews with Dr Martens on the MOBILE Study, please see:

CGM vs SMBG in Primary Care: What Does the T2D Evidence Say?

Thomas W. Martens, MD: MOBILE Study Findings on CGM vs BGM in T2 Diabetes

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.